Compare CIEN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIEN | CORT |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.7B | 3.7B |
| IPO Year | 1996 | 2001 |
| Metric | CIEN | CORT |
|---|---|---|
| Price | $492.96 | $73.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $382.69 | $96.50 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 06-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $4,769,507,000.00 | $761,407,000.00 |
| Revenue This Year | $30.83 | $26.08 |
| Revenue Next Year | $19.87 | $26.98 |
| P/E Ratio | $519.29 | ★ N/A |
| Revenue Growth | ★ 18.79 | 12.79 |
| 52 Week Low | $70.85 | $28.66 |
| 52 Week High | $637.51 | $91.00 |
| Indicator | CIEN | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 80.07 |
| Support Level | $471.47 | $68.20 |
| Resistance Level | $513.49 | $79.89 |
| Average True Range (ATR) | 37.52 | 2.57 |
| MACD | -9.92 | 0.87 |
| Stochastic Oscillator | 2.91 | 87.98 |
Ciena is a leader in high-speed optical connectivity, providing systems, components, and automation software for telecom providers and enterprises, such as data centers, to enable long-distance connectivity. The company operates through four primary business segments: networking platforms, platform software and services, Blue Planet automation software, and global services. While telecom carriers remain important customers, cloud providers and hyperscalers now drive a significant portion of the business. To meet the demands of AI data centers, customers are adopting Ciena's WaveLogic 6 platform, the first to support 1.6 terabits-per-second capacity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.